Back

Transcriptome- and proteome-wide Mendelian randomization to prioritize therapeutic targets for coronary heart disease

Gaziano, L.; Allara, E.; Giambartolomei, C.; Stacey, D.; Zhao, J. H.; Dashti, H.; Jiang, T.; Ritchie, S. C.; Ferolito, B.; Rasooly, D.; Peloso, G. M.; Di Angelantonio, E.; Wheeler, E.; Pietzner, M.; Assimes, T. L.; Wilson, P. W.; Cho, K.; Aragam, K.; Burgess, S.; Danesh, J.; Langenberg, C.; Casas, J. P.; Gaziano, J. M.; Pereira, A. C.; Butterworth, A. S.

2024-06-28 cardiovascular medicine
10.1101/2024.06.27.24309406 medRxiv
Show abstract

Despite widespread use of drugs targeting traditional cardiovascular risk factors such as lipids and blood pressure, a high burden of coronary heart disease (CHD) remains, hence novel therapeutics are needed for people who harbor residual risk. Using transcriptomic and proteomic data to instrument 15,527 genes or proteins, we conducted systematic cis-Mendelian randomization (MR) and conditional colocalization analyses with a genetic meta-analysis involving nearly 300,000 CHD cases. We identified 567 targets with putative causal relevance to CHD, of which 69 were not identified in previous genetic discovery or MR studies and were the sole causal signal in that genomic region. To aid translation of our findings, we annotated results with up-to-date information on drugs acting on these targets. Our results revealed opportunities for drug repurposing and development prioritization. For example, we provide evidence that cilostazol, a drug that targets PDE3A and is currently used for claudication, could be repurposed for prevention of CHD.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.